Lichen Planus Treatment Guidelines

First-Line Treatment Approach

The American Academy of Dermatology recommends high-potency topical corticosteroids, such as clobetasol propionate 0.05% gel, as the standard of care for lichen planus, with treatment lasting 2-3 months followed by gradual tapering over 3 weeks 1, 2, 3
For oral lichen planus, gel formulations are mandatory due to their appropriate mucosal adherence, and cream or ointment formulations should never be used intraorally 1, 3
Tacrolimus 0.1% ointment is recommended as an alternative first-line option when corticosteroids are contraindicated or ineffective 1, 2, 3

The American Academy of Dermatology suggests low-dose methotrexate as a second-line systemic option for refractory lichen planus, with typical dosing at 15 mg/week 4
IL-17 inhibitors, such as secukinumab and ixekizumab, represent newer treatment options for refractory lichen planus, particularly when disease is dose-limiting 4, 5
Tofacitinib is a newer oral systemic option for refractory lichen planus, listed as a second-line option alongside traditional immunosuppressants 4, 5

Narrow-band UVB phototherapy is an option for moderate to severe disease 2, 3
Intralesional triamcinolone acetonide is effective for nail matrix involvement and refractory localized lesions 2, 4, 5
Doxycycline with nicotinamide may be considered for refractory cases 2, 3

The American Academy of Dermatology advises against abruptly discontinuing topical corticosteroids, recommending a gradual taper over 3 weeks to prevent rebound flares 1, 3
Patients using potent steroids should be monitored for cutaneous atrophy, adrenal suppression, hypopigmentation, and contact sensitivity 1

The American Academy of Dermatology recommends scheduling follow-up at 3 months to assess treatment response and monitor for adverse effects 1, 2
Patients should report any persistent ulceration or new growth, as oral lichen planus carries a small risk of malignant transformation to squamous cell carcinoma 1